semaglutide being banned Will compounded be banned? GLP-1 weight-loss drugs are a
Description
Pancreatitis risk: There is a potential risk of pancreatitis associated with tirzepatide use
Retatrutide's reported fat-to-lean ratio sits in the same neighborhood
Obes Surg (2018) 28:353843
OASIS-4 (25 mg Oral Semaglutide) Mean weight reduction: 13.6% Placebo-adjusted difference: 11.4% Reducing the dose by half resulted in only ~1.5% loss in efficacy, suggesting a near-saturation point in receptor activation around 25 mg
Before Retatrutide, every weight loss attempt fell apart within weeks
doi: 10.5551/jat.60921, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 89
